Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

March 15, 2006 (Vol. 26, No. 6)

CMOs Find Opportunities in Biologics

Biomanufacturing Companies Provide Services From Preclinicals through All Clinical Phases

  • The first attempts to use monoclonals (Mabs) as antitumor agents in the 1980s did not live up to expectations. The recent success of improved therapeutic Mabs, such as Rituxan for cancer and Remicade for arthritis, are proving clinically effective and financially attractive. This resurgent interest in Mabs creates opportunities ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.